Alnylam Pharmaceuticals

Biotechnology

Alnylam pioneered RNA interference (RNAi) therapeutics, developing medicines that silence disease-causing genes. The company has multiple approved drugs for rare diseases including hereditary ATTR amyloidosis and acute hepatic porphyria. Alnylam's platform technology validates RNAi as a therapeutic modality after decades of development.

The Biology of Business

Sign up to be notified when the book is available to order.

Notify Me